Oregon Health & Science University
Portland, Oregon, 97239, United States
Location status: Recruiting
Location contact
Denzil Romfh, OD
CONTACT
Humberto Martinez, COT
CONTACT
NCT Number: NCT03761381
The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to:
1. Detect retinal blood vessel and blood flow changes in participants with dementia. 2. Detect amyloid protein deposits in the retinas of participants with dementia.
Interested in participating?
Request Info55 year and older
All sexes
Observational
Portland, Oregon, 97239, United States
Location status: Recruiting
Denzil Romfh, OD
CONTACT
Humberto Martinez, COT
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for dementia subjects:
Inclusion criteria
for dementia-free controls:
Exclusion criteria
for both dementia and dementia-free subjects:
Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.
The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.
Time frame: 1 day
OCT and OCT angiography will be used to detect levels of amyloid proteins deposits within the retina layers on the single enrollment visit only. An increase in the protein detection is expected in the dementia group.
Time frame: 1 day
OCT and OCT angiography will be used to detect blood flow in dementia vs dementia-free controls. OCT and OCTA imaging will be taken on the single enrollment visit only. Decreased blood flow is expected in the dementia group.
Time frame: 1 day
OCT and OCT angiography will be used to detect retinal perfusion deficits in dementia vs dementia-free controls. OCT and OCTA imaging will be taken on a single enrollment visit only. Decreased retinal perfusion is expected in the dementia group.
Contact information is provided by the study sponsor or research team.
Denzil Romfh, OD
CONTACT
Humberto Martinez, COT
CONTACT
Oregon Health and Science University
Other
Using Optical Coherence Tomography and Noninvasive Retinal Amyloid Imaging to Capture Retinal Changes Associated With Dementia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07717567
Alzheimer Disease, Brain Diseases
Milan, Milano, Italy
View Trial DetailsNCT07602283
Alzheimer Disease, Anxiety Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07012993
Alzheimer Disease, Brain Diseases
Englewood, New Jersey, United States
View Trial DetailsNCT05561205
Alzheimer Disease, Apathy in Dementia
Toronto, Ontario, Canada
View Trial Details